Want to see AXGN full AI Analyst Report?
AXGN Stock Chart & Stats
$51.58
-$0.24(-0.60%)
At close: 4:00 PM EDT
$51.58
-$0.24(-0.60%)
Day’s Range― - ―
52-Week Range$17.14 - $52.91
Previous CloseN/A
Volume750.55K
Average Volume (3M)1.51M
Market Cap
$2.12B
Enterprise Value$2.37B
Total Cash (Recent Filing)$94.57M
Total Debt (Recent Filing)$20.07M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Oct 28, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend Yield22.22%
Share Statistics
EPS (TTM)-0.67
Shares Outstanding58,671,513
10 Day Avg. Volume1,271,344
30 Day Avg. Volume1,514,131
Financial Highlights & Ratios
PEG Ratio-2.01
Price to Book (P/B)11.70
Price to Sales (P/S)6.69
P/FCF Ratio-513.89
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue9.44
Enterprise Value/Gross Profit12.66
Enterprise Value/Ebitda-189.50
Forecast
1Y Price Target
$53.25Price Target Upside3.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.46
Revenue Forecast (FY)$283.33M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthA raised growth outlook supported by strong quarterly execution indicates continued demand for AxoGen’s nerve-repair portfolio. Expanding surgeon activity, active accounts, and breast-market adoption can strengthen scale and support durable revenue growth over the next several quarters.
Strong Product EconomicsGross margin in the mid-70% range demonstrates attractive economics for AxoGen’s specialized products and provides resources to fund commercial expansion, clinical evidence, and innovation. This profitability foundation can remain durable even as the company broadens its procedure and product mix.
De-risked Balance SheetVery low leverage and a sizable equity base give AxoGen meaningful financial flexibility while it remains in an investment phase. The stronger capital position can support product development, commercial initiatives, and strategic opportunities without the same balance-sheet strain associated with heavier borrowing.
Bears Say
Persistent GAAP LossesOngoing operating and net losses show that AxoGen’s strong revenue and gross-margin profile has not yet translated into sustainable GAAP profitability. If losses persist, they may constrain internally funded investment, pressure equity value, and make execution increasingly dependent on future growth.
Product-Mix Margin PressureThe fastest-growing product and indication areas currently carry higher production costs, creating a structural risk that mix-driven expansion will dilute margins. Pricing and production-efficiency actions are expected to take time, so margin recovery may lag revenue growth through the near term.
Rising Operating ExpensesHeavy investment in commercial expansion and higher compensation costs are absorbing more of the company’s gross profit, limiting operating leverage despite robust sales growth. Unless account productivity scales faster than spending, elevated expenses could prolong losses and delay durable earnings conversion.
AxoGen News
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $17.14 and its highest was $52.91 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $2.12B.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Oct 28, 2026 which is in 5 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on Jul 29, 2026. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.121 by -$0.001.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of 22.22%. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.13.
How many shares outstanding does AxoGen have?
AxoGen has 58,671,513 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of $0.12 in its last earnings report, missing expectations of $0.121. Following the earnings report the stock price went up 0.535%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AxoGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.25 (3.24% Upside)
$53.25 (3.24% Upside)
Blogger Sentiment
Bullish
AXGN Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 17.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 19.0%
Last 30 Days ▲ 19.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
103.21%
12-Months-Change
Fundamentals
Return on Equity
-17.88%
Trailing 12-Months
Asset Growth
48.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AxoGen
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
AXGN Company Deck
AXGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong operational and commercial momentum: robust revenue growth (Q2 +23.1%), a pronounced acceleration in the Breast market (YTD +47%) that materially expanded Avance volume and adoption, growing active surgeon and account metrics, cash balance strength and raised revenue guidance. Offsetting this optimism are near-term margin pressures driven by an accelerated shift in product mix toward longer, higher-cost Avance grafts, increased operating expenses tied to commercial investment, and pending payer decisions (notably Aetna) that could further accelerate adoption but remain unquantified. Management outlined actionable plans (pricing and production efficiency initiatives) but emphasized these will take time to influence 2026 results. Overall, positives (strong top-line, guidance raise, evidence progress, healthy cash position and commercial momentum) outweigh the manageable operational and margin challenges disclosed.View all AXGN earnings summariesAXGN Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$53.25
▲(3.24% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Integra Lifesciences
―
Orthofix Medical
―
Xtant Medical Holdings
―
TELA Bio
―
Bioventus
―
Ownership Overview
1.43% Insiders
18.35% Mutual Funds
6.38% Other Institutional Investors
59.28% Public Companies and
Individual Investors










